AstraZeneca builds pipeline with $232 million Synairgen asthma deal

Reuters
0

By Ben Hirschler

LONDON (Reuters) - AstraZeneca (AZN.L) has struck a deal worth up to $232 million (137.86 million pounds) in milestone payments to acquire rights to a drug from Synairgen (SYNG.L) for treating respiratory tract viral infections in patients with severe asthma.

Britain's second-biggest drugmaker - subject of a $118 billion bid by Pfizer (PFE.N) that failed last month - said on Thursday it would pay UK-based Synairgen a $7.25 million upfront fee and potential development, regulatory and commercial milestones of up to $225 million for rights to the drug, codenamed SNG001.

The deal, which sent in shares in Synairgen surging 46 percent by 0740 GMT (8:40 a.m. BST), marks a continuation of AstraZeneca's strategy of striking bolt-on product licensing deals in key therapeutic areas, such as respiratory medicine.

Some analysts have speculated AstraZeneca might also consider a much larger acquisition to try to see off the threat of a renewed Pfizer approach. But others believe the British firm will come under pressure from shareholders to revive talks with its larger U.S. rival.

Under British takeover law, AstraZeneca can reach out to Pfizer in late August to discuss a sweetened bid, or Pfizer could make renewed overtures in November, whether it is invited back or not.

Pfizer Chief Financial Officer Frank D'Amelio, speaking to the Goldman Sachs (GS.N) annual healthcare conference on Wednesday, said talks about a deal with AstraZeneca had fallen down over price, rather than any other issues.

Synairgen's SNG001 is an inhaled interferon beta medicine that was originally invented at the University of Southampton, southern England.

AstraZeneca plans to start a mid-stage Phase IIa study with the drug in early 2015 in patients with severe asthma, building on results from an initial Phase lla trial in a broad asthma population.

Severe asthma is a growing focus for major drugmakers, which are looking to a range of novel biotech medicines to help difficult-to-treat patients.

"SNG001 is an innovative and targeted therapy that has, if successful, the potential to offer a step-change in the treatment of severe asthma, and possibly COPD (chronic obstructive pulmonary disease),” said Maarten Kraan, AstraZeneca's head of respiratory, inflammation and autoimmune medicines.

In addition to making milestone payments and covering the future development costs for SNG001, AstraZeneca will also pay tiered royalties ranging from a single-digit up to mid-teens percentage rate on any eventual commercial sales.

Synairgen shares were up 24 pence or 45 percent at 76.03p by 0749 GMT, having risen as high as 85.95p, their highest since 2006.

(Editing by Paul Sandle and David Holmes)

Advertisement

Recommended Stories

  • Dow Jones Falls As Donald Trump Stock Craters; Cathie Wood Buys This Stock Amid 51% Plunge

    The Dow Jones fell as Elon Musk made a Tesla move. The Donald Trump stock sank on the stock market today. Cathie Wood bought a diving stock.

  • Trump Media stock tanks 18% on move to issue millions of shares

    Trump Media stock slid as much as 16% on Monday after the parent company of Donald Trump's social media platform, Truth Social, filed to issue more than 21 million shares.

  • Stocks, Currencies Tumble Amid Broad Selloff: Markets Wrap

    (Bloomberg) -- European equity futures tracked the grim Asian session as signs of fading momentum in China’s economy added to angst over elevated US interest rates and tensions in the Middle East.Most Read from BloombergBeyond the Ivies: Surprise Winners in the List of Colleges With the Highest ROITrump Media’s $5.3 Billion Selloff Deepens as 270% Rally FizzlesS&P 500 Breaks Below 5,100 as Big Tech Sells Off: Markets WrapIran’s Attack on Israel Sparks Race to Avert a Full-Blown WarApple Faces Wo

  • Tesla layoffs hit high performers, some departments slashed, sources say

    Tesla management told employees Monday that the recent layoffs -- which gutted some departments by 20% and even hit high performers -- were largely due to poor financial performance, a source familiar with the matter told TechCrunch. The layoffs were announced to staff just a week before Tesla is scheduled to report its first-quarter earnings. The move comes as Tesla has seen its profit margin narrow over the past several quarters, the result of an EV price war that has persisted for at least a year.

  • Jim Cramer Says People Think Elon Musk Might Be Losing His Edge Or 'Turning Into An Evil Genius,' But Warren Buffett Never Fails To Deliver

    TV personality Jim Cramer addressed differing investor sentiments toward titans of Wall Street Elon Musk and Warren Buffett on April 12 on CNBC. Cramer highlighted that while Buffett continues to earn investor admiration, Musk has faced criticism because of Tesla Inc.'s declining share price. Don't Miss: Are you rich? Here’s what Americans think you need to be considered wealthy. Can you guess how many Americans successfully retire with $1,000,000 saved? The percentage may shock you. "We operate

  • Elon Musk Agrees With Jamie Dimon's Warning Of Political Polarization 'Creating Risks That Could Eclipse Anything Since World War II'

    JP Morgan Chase & Co. (NYSE:JPM) CEO Jamie Dimon's annual shareholder letter is a moment investors await to understand the thinking of one of the world's most influential bankers. While there has been speculation of Dimon entering politics, with him even gaining the support of billionaire hedge fund manager Bill Ackman to run for president, JP Morgan shared in a statement that "Jamie has no plans to run for office" and that "he is very happy in his current role." That has not stopped him from oc

  • 1 Magnificent Dividend Stock Down 27% to Buy Right Now Near a Once-in-a-Decade Valuation

    This consumer staples behemoth and potential cornerstone holding is available at what could prove to be a significant discount.

  • Dow Jones Futures: Another Ugly Market Reversal; Nvidia Skids, Tesla Tumbles On 'Dark Day'

    Mideast fears and surging yields triggered another ugly market reversal. Nvidia and Microsoft fell while Tesla dived.

  • 4 Oversold Stocks to Buy Right Now

    Here are four stocks to buy now that could offer investors upside in the short and long term.

  • Bitcoin Halving May Lead to Some Sales, Crypto.com CEO Says

    (Bloomberg) -- Bitcoin selling may become evident as the date of the so-called halving nears but the event is set to bolster the price of the largest digital asset longer term, according to the head of the Crypto.com exchange.Most Read from BloombergBeyond the Ivies: Surprise Winners in the List of Colleges With the Highest ROITrump Media’s $5.3 Billion Selloff Deepens as 270% Rally FizzlesS&P 500 Breaks Below 5,100 as Big Tech Sells Off: Markets WrapIran’s Attack on Israel Sparks Race to Avert